title: Differential contribution of bacterial N-formyl-methionyl-leucyl- phenylalanine and host-derived CXC chemokines to neutrophil infiltration into pulmonary alveoli during murine pneumococcal pneumonia.
abstract: Despite the development of new potent antibiotics, Streptococcus pneumoniae remains the leading cause of death from bacterial pneumonia. Polymorphonuclear neutrophil (PMN) recruitment into the lungs is a primordial step towards host survival. Bacterium-derived N-formyl peptides (N-formyl-methionyl-leucyl-phenylalanine [fMLP]) and host-derived chemokines (KC and macrophage inflammatory protein 2 [MIP-2]) are likely candidates among chemoattractants to coordinate PMN infiltration into alveolar spaces. To investigate the contribution of each in the context of pneumococcal pneumonia, CD1, BALB/c, CBA/ca, C57BL/6, and formyl peptide receptor (FPR)-knockout C57BL/6 mice were infected with 10(6) or 10(7) CFU of penicillin/erythromycin-susceptible or -resistant serotype 3 or 14 S. pneumoniae strains. Antagonists to the FPR, such as cyclosporine H (CsH) and chenodeoxycholic acid, or neutralizing antibodies to KC and MIP-2 were injected either 1 h before or 30 min after infection, and then bronchoalveolar lavage fluids were obtained for quantification of bacteria, leukocytes, and chemokines. CsH was effective over a short period after infection with a high inoculum, while anti-CXC chemokine antibodies were effective after challenge with a low inoculum. CsH prevented PMN infiltration in CD1 mice infected with either serotype 3 or 14, whereas antichemokine antibodies showed better efficacy against the serotype 3 strain. When different mouse strains were challenged with serotype 3 bacteria, CsH prevented PMN migration in the CD1 mice only, whereas the antibodies were effective against CD1 and C57BL/6 mice. Our results suggest that fMLP and chemokines play important roles in pneumococcal pneumonia and that these roles vary according to bacterial and host genetic backgrounds, implying redundancy among chemoattractant molecules.
authors: Research Center for Infectious Diseases, Laval University, Quebec, Canada G1V 4G2.
authors: Jean-François
authors: JF
authors: Gauthier
authors: Andrée
authors: A
authors: Fortin
authors: Yves
authors: Y
authors: Bergeron
authors: Marie-Christine
authors: MC
authors: Dumas
authors: Marie-Eve
authors: ME
authors: Champagne
authors: Michel G
authors: MG
authors: Bergeron
mesh_terms: D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology / Q000382:microbiology; D019743:Chemokines, CXC / Q000276:immunology*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D018345:Mice, Knockout; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000276:immunology*; D020556:Neutrophil Infiltration / Q000276:immunology*; D011018:Pneumonia, Pneumococcal / Q000276:immunology*; D011650:Pulmonary Alveoli / Q000276:immunology*; D044042:Receptors, Formyl Peptide / Q000172:deficiency; D013296:Streptococcus pneumoniae / Q000276:immunology*
chemical_list: D019743:Chemokines, CXC; D044042:Receptors, Formyl Peptide; D009240:N-Formylmethionine Leucyl-Phenylalanine
references: Int J Biochem Cell Biol. 1998 Feb;30(2):173-8
references: 9608670
references: Infect Immun. 1998 Mar;66(3):912-22
references: 9488375
references: J Exp Med. 1999 Sep 6;190(5):741-7
references: 10477558
references: Traffic. 2005 Feb;6(2):83-6
references: 15634209
references: J Leukoc Biol. 2005 Feb;77(2):257-66
references: 15561756
references: Annu Rev Immunol. 2005;23:821-52
references: 15771587
references: Eur J Immunol. 2005 Aug;35(8):2486-95
references: 16025565
references: Respir Res. 2005;6:126
references: 16255775
references: J Immunol. 2005 Dec 1;175(11):7530-5
references: 16301661
references: Arch Immunol Ther Exp (Warsz). 2005 Nov-Dec;53(6):505-17
references: 16407783
references: Cell Microbiol. 2006 Feb;8(2):207-17
references: 16441432
references: Curr Biol. 2006 Feb 21;16(4):401-7
references: 16488875
references: Eur J Pharmacol. 2006 Mar 18;534(1-3):1-11
references: 16516193
references: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2857-62
references: 16481624
references: J Clin Microbiol. 2006 Jun;44(6):2032-8
references: 16757594
references: Crit Care Med. 2006 Jul;34(7):1947-54
references: 16715037
references: J Immunol. 2000 Jan 1;164(1):404-11
references: 10605036
references: Curr Opin Hematol. 2000 May;7(3):178-82
references: 10786656
references: J Biol Chem. 2000 Nov 24;275(47):37257-63
references: 10967103
references: Infect Immun. 2001 Jan;69(1):426-34
references: 11119534
references: J Infect Dis. 2001 Jan 1;183(1):70-7
references: 11087202
references: J Immunol. 2001 Jun 15;166(12):7353-61
references: 11390486
references: J Infect Dis. 2001 Aug 1;184(3):292-300
references: 11443554
references: J Leukoc Biol. 2002 Feb;71(2):262-70
references: 11818447
references: Infect Immun. 2002 Mar;70(3):1547-57
references: 11854243
references: Infect Immun. 2002 Aug;70(8):4226-38
references: 12117931
references: Curr Drug Targets Immune Endocr Metabol Disord. 2003 Mar;3(1):33-42
references: 12570724
references: Shock. 2004 Nov;22(5):460-6
references: 15489639
references: J Infect Dis. 1986 Apr;153(4):682-93
references: 3950449
references: Adv Exp Med Biol. 1991;305:73-7
references: 1755381
references: J Antimicrob Chemother. 1991 Dec;28 Suppl C:45-53
references: 1664829
references: Blood. 1995 Sep 1;86(5):1649-60
references: 7654998
references: J Biol Chem. 1999 Mar 5;274(10):6027-30
references: 10037679